DOCSLIB.ORG

KPCO Pharmacy Authorization Guidelines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
KPCO Pharmacy Authorization Guidelines COLORADO - MEDICATION AUTHORIZATION GUIDELINES DROXIDOPA Generic Brand HICL GCN Exception/Other DROXIDOPA NORTHERA 40936 INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is this being prescribed by a neurologist or cardiologist? If yes, continue to #2. If no, do not approve. 2. Is the patient 18 years of age or older? If yes, continue to #3. If no, do not approve. 3. Does the patient have a confirmed diagnosis of neurogenic hypotension due to Parkinson’s disease, pure autonomic failure, multisystem atrophy, non-diabetic autonomic neuropathy, or dopamine-β-hydroxylase deficiency? If yes, continue to #4. If no, do not approve. 4. Does the patient have ischemic heart disease, arrhythmias, congestive heart failure, or sustained, severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg sitting or supine)? If yes, do not approve. If no, continue to #5. 5. Does the patient have aspirin hypersensitivity or a yellow dye allergy? If yes, do not approve. If no, continue to #6. 6. Does the patient have severe renal impairment (CrCl less than 30 mL/min)? If yes, do not approve. If no, continue to #7. 7. Is the patient currently breastfeeding? If yes, do not approve. If no, continue to #8. Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES 8. Is the patient currently utilizing a non-selective MAO inhibitor, linezolid, or tedizolid*? If yes, do not approve. If no, continue to #9. 9. Is the patient symptomatic despite using non-pharmacological interventions (getting up slowly, wearing elastic stockings, adequate salt and fluid intake, elevating the head of the bed, leg-crossing, thigh contraction, etc.)? If yes, continue to #10. If no, do not approve. 10. Has the patient tried and failed fludrocortisone and midodrine individually and as a combination? If yes, approve GENERIC only x3 months, max daily dose #6. If no, do not approve. RENEWAL CRITERIA 1. Has the patient developed symptoms of neuroleptic malignant syndrome; ischemic heart disease; arrhythmias; congestive heart failure; sustained, severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg sitting or supine); severe renal impairment (CrCl less than 30 mL/min); or has the patient started a non-selective MAO inhibitor, linezolid, tedizolid*, or breast-feeding? If yes, do not approve. If no, continue to #2. 2. Have the patient’s symptoms improved? If yes, approve GENERIC Only x6 months, max daily dose #6. If no, do not approve. *Possible theoretical interaction for tedizolid. Creation date: 11/16/2016 Effective date: 1/1/2017 Reviewed date: 7/1/2020 Revised date: 11/1/2016 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES BECAPLERMIN Generic Brand HICL GCN Exception/Other BECAPLERMIN REGRANEX 17028 Becaplermin will be provided as a plan benefit within the following guidelines: 1. Is the patient diagnosed with diabetes mellitus? If yes, continue to #2. If no, continue to #4. 2. Is the prescription written by a vascular surgeon, podiatrist, or endocrinologist? If yes, continue to #3. If no, continue to #4. 3. Is there a diagnosed neoplasm (i.e., cancer), necrotic tissue, infection, or osteomyelitis at site of application? If yes, continue to #4. If no, approve for 3 months for two (2) tubes per month maximum. 4. Is the prescription a hospital discharge prescription per the member, prescriber, or pharmacy? If yes, approve for 3 months for two (2) tubes per month maximum. If no, do not approve. RENEWAL CRITERIA 1. Has there been at least a 30% decrease in wound size? If yes, approve for a period of time necessry to complete a 20 week course, including the previous approvals, for two (2) tubes per month maximum If no, do not approve Creation date: 11/16/2016 Effective date: 1/1/2017 Reviewed date: 9/1/2020 Revised date: 11/1/2017 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES INSULIN GLARGINE (VIALS) Generic Brand HICL GCN Exception/Other INSULIN LANTUS (VIALS) 13072 GLARGINE Approval for the use of insulin glargine vials is based upon meeting one of the following criteria: • Patient has type 1 diabetes. • Prescription is written by CPMG affiliated Endocrinology (Pediatric or Adult) specialist. • Patient has type 2 diabetes with severe hypoglycemia despite appropriate insulin management (i.e., basal insulin, bolus/mealtime insulin, hypoglycemia management). Severe hypoglycemia can be defined as: o 2-3 episodes <70 mg/dl on separate days in a week o Any event resulting in coma/seizure o Any event requiring the assistance of another person with glucagon or emergency services. Creation date: 5/25/2018 Effective date: 6/11/2018 Reviewed date: 5/1/2020 Revised date: 5/1/2018 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES LAMOTRIGINE, EXTENDED-RELEASE Generic Brand HICL GCN Exception/Other LAMOTRIGINE, LAMICTAL XR 24703, EXTENDED- 24739, RELEASE 24693, 30787, 29725, 24697, 24851, 24856, 24869 GUIDELINES FOR USE Note: The 200 mg and 300 mg strength are formulary. All other strengths are non- formulary. INITIAL CRITERIA 1. Is this being prescribed by a neurologist, in consultation with a neurologist, or was this formulation originally started by a neurologist? If yes, continue to #2. If no, do not approve. 2. Does the patient have a diagnosis of epilepsy or a history of seizures? If yes, continue to #3. If no, do not approve. 3. Has the patient tried and failed immediate-release (IR) lamotrigine? If yes, continue to #4. If no, do not approve. 4. Is the patient at risk for breakthrough seizures because of missed doses or the drug not lasting long enough during the day (i.e., having early morning seizure breakthrough)? If yes, continue to #5. If no, do not approve. 5. Is the request for a formulary strength of lamotrigine XR/SR? If yes, approve open-ended. If no, go to #6. Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES 6. Can the patient’s daily dose be achieved by a formulary strength of lamotrigine XR/SR? If yes, approve the appropriate formulary strength of lamotrigine open-ended. If no, approve the non-formulary strength of lamotrigine x 1 year. RENEWAL CRITERIA 1. Can the patient’s daily dose be achieved by a formulary strength of lamotrigine XR/SR? If yes, approve the appropriate formulary strength of lamotrigine open-ended. If no, approve the non-formulary strength of lamotrigine x 1 year. Creation date: 7/25/2018 Effective date: 8/15/2018 Reviewed date: 7/1/2020 Revised date: 7/1/2018 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES LUMACAFTOR/IVACAFTOR Generic Brand HICL GCN Exception/Other LUMACAFTOR/IVACAFTOR ORKAMBI 42235 GUIDELINES FOR USE (RENEWAL CRITERIA BELOW) 1. Is the patient 2 years old or older? If yes, continue to #2. If no, do not approve. 2. Is this medication prescribed by a pulmonologist? If yes, continue to #3. If no, do not approve. 3. Does the patient have a diagnosis of cystic fibrosis, and is the patient homozygous for the F508del mutation (as verified by testing)? If yes, continue to #4 If no, do not approve. 4. Is the patient of age 6 years or older? If yes, continue to #5. If no, approve x12 months at HICL, maximum daily dose of two. 5. Does the patient have a baseline FEV1 of at least 40% as documented by lab report or chart notes (not required for patients younger than 6 years of age)? If yes, approve x1 fourteen-day fill (#56 tablets). Also, enter an approval x1 year @ HICL, max daily dose #4 to start the day the fourteen-day supply ends. If no, do not approve. RENEWAL CRITERIA 1. Is there documentation of improvement in the patient’s CF as indicated by a maintained or improved FEV1 or BMI, reductions in pulmonary exacerbations, or improved quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score? If yes, approve x 2 years at HICL. If no, do not approve. Creation date: 9/15/2018 Effective date: 10/12/2018 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES Reviewed date: 7/1/2020 Revised date: 9/1/2018 Effective: July 2021 NOTE: these guidelines may change at any time COLORADO - MEDICATION AUTHORIZATION GUIDELINES IVACAFTOR Generic Brand HICL GCN Exception/Other IVACAFTOR KALYDECO 38461 GUIDELINES FOR USE INITIAL CRITERIA (see below for renewal criteria) 1. Is this medication prescribed by a pulmonologist? If yes, continue to #2. If no, do not approve. 2. Is the patient 6 months old? If yes, continue to #3. If no, do not approve. 3. Does the patient have a diagnosis of cystic fibrosis (CF) with documentation of at least one of the following mutations in the CFTR gene that is responsive to ivacaftor (Kalydeco)? E56K, P67L, R74W, D579G, G1069R, D1270N, G178R, E193K, L206W, A1067T, S1255P, R117H, S549R, G551D, G551S, S1251N, R117C, S549N, 711+3A→G, F1052V, K1060T, D110H, A455E, S945L, 3272-26A→G, D1152H, G1244E, R352Q, E831X, R1070W, 2789+5G→A, D110E, R347H, G1349D, R1070Q, S977F, 3849+10kbC→T, F1074L If yes, continue to #4. If no, do not approve. 4. Is the patient homozygous for the F508del-CFTR mutation? If yes, do not approve. If no, continue to #5. 5. Is the patient of age 6 years or older? If yes, continue to #6. If no, approve for 12 months at HICL with a quantity limit of #2 per day. 6. Does the patient have a baseline FEV1 of at least 40% as documented by lab report or chart notes (not required for patients younger than 6 years of age)? If yes, approve for 12 months at HICL with a quantity limit of #2 per day.
Load more

Recommended publications
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition
    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
    [Show full text]
  • Fasted and Fed State Human Duodenal Fluids: Characterization, Drug Solubility, and Comparison to Simulated Fluids and with Human Bioavailability
    European Journal of Pharmaceutics and Biopharmaceutics 163 (2021) 240–251 Contents lists available at ScienceDirect European Journal of Pharmaceutics and Biopharmaceutics journal homepage: www.elsevier.com/locate/ejpb Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability D. Dahlgren a, M. Venczel b,c, J.-P. Ridoux b,c, C. Skjold¨ a, A. Müllertz d, R. Holm e, P. Augustijns f, P.M. Hellstrom¨ g, H. Lennernas¨ a,* a Department of Pharmaceutical Biosciences, Biopharmaceutics, Uppsala University, Sweden b Global CMC Development Sanofi, Frankfurt, Germany c Global CMC Development Sanofi, Vitry, France d Physiological Pharmaceutics, University of Copenhagen, Copenhagen, Denmark e Drug Product Development, Janssen R&D, Johnson & Johnson, Beerse, Belgium f Drug Delivery and Disposition, KU Leuven, Leuven, Belgium g Department of Medical Sciences, Gastroenterology/Hepatology, Uppsala University, Sweden ARTICLE INFO ABSTRACT Keywords: Accurate in vivo predictions of intestinal absorption of low solubility drugs require knowing their solubility in Bioavailability physiologically relevant dissolution media. Aspirated human intestinal fluids (HIF) are the gold standard, fol­ Food effects lowed by simulated intestinal HIF in the fasted and fed state (FaSSIF/FeSSIF). However, current HIF charac­ Drug solubility terization data vary, and there is also some controversy regarding the accuracy of FaSSIF and FeSSIF for Human intestinal fluids predicting drug solubility in HIF. This study aimed at characterizing fasted and fed state duodenal HIF from 16 Drug absorption Drug dissolution human volunteers with respect to pH, buffer capacity, osmolarity, surface tension, as well as protein, phos­ Drug delivery pholipid, and bile salt content.
    [Show full text]
  • Pharmacokinetic Interactions of Pioglitazone
    Department of Clinical Pharmacology University of Helsinki Finland PHARMACOKINETIC INTERACTIONS OF PIOGLITAZONE Tiina Jaakkola ACADEMIC DISSERTATION To be presented, with the permission of the Medical Faculty of the University of Helsinki, for public examination in Auditorium 2 of Biomedicum, on August 24th, 2007, at 12 noon. Helsinki 2007 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 1 117.7.20077.7.2007 221:11:231:11:23 Supervisors: Professor Pertti Neuvonen, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Docent Janne Backman, MD Department of Clinical Pharmacology University of Helsinki Helsinki, Finland Reviewers: Docent Kimmo Malminiemi, MD, MSc Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland Professor emeritus Pertti Pentikäinen, MD Department of Medicine University of Helsinki Helsinki, Finland Opponent: Professor Kari Kivistö, MD Department of Pharmacology, Clinical Pharmacology and Toxicology University of Tampere Tampere, Finland ISBN 978-952-92-2224-7 (paperback) ISBN 978-952-10-4020-7 (PDF, http://ethesis.helsinki.fi ) Helsinki 2007 Yliopistopaino JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 2 117.7.20077.7.2007 221:11:551:11:55 JJaakkola_Tiina_vaitos.inddaakkola_Tiina_vaitos.indd 3 117.7.20077.7.2007 221:11:551:11:55 CONTENTS CONTENTS ABBREVIATIONS.......................................................................................................................................... 6 LIST OF ORIGINAL PUBLICATIONS.......................................................................................................
    [Show full text]
  • Pharmacokinetic Interactions of Drugs with St John's Wort
    http://www.paper.edu.cn Pharmacokinetic interactions of Journal of Psychopharmacology 18(2) (2004) 262–276 © 2004 British Association drugs with St John’s wort for Psychopharmacology ISSN 0269-8811 SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi 10.1177/0269881104042632 Shufeng Zhou Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Eli Chan Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore. Shen-Quan Pan Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore. Min Huang Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510089, PR China. Edmund Jon Deoon Lee Department of Pharmacology, Faculty of Medicine, National University of Singapore, Singapore. Abstract There is a worldwide increasing use of herbs which are often cancer patients receiving irinotecan treatment. St John’s wort did not administered in combination with therapeutic drugs, raising the alter the pharmacokinetics of tolbutamide, but increased the incidence potential for herb–drug interactions. St John’s wort (Hypericum of hypoglycaemia. Several cases have been reported that St John’s wort perforatum) is one of the most commonly used herbal antidepressants. A decreased cyclosporine blood concentration leading to organ rejection. literature search was performed using Medline (via Pubmed), Biological St John’s wort caused breakthrough bleeding and unplanned pregnancies Abstracts, Cochrane Library, AMED, PsycINFO and Embase (all from their when used concomitantly with oral contraceptives. It also caused inception to September 2003) to identify known drug interaction with serotonin syndrome when coadministered with selective serotonin- St John’s wort. The available data indicate that St John’s wort is a reuptake inhibitors (e.g.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • ACCOLATE® (Zafirlukast) TABLETS DESCRIPTION
    ACCOLATE® (zafirlukast) TABLETS DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist (LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o­ tolylsulfonylbenzamide. The molecular weight of zafirlukast is 575.7 and the structural formula is: The empirical formula is: C31H33N3O6S Zafirlukast, a fine white to pale yellow amorphous powder, is practically insoluble in water. It is slightly soluble in methanol and freely soluble in tetrahydrofuran, dimethylsulfoxide, and acetone. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium, lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose, and titanium dioxide. CLINICAL PHARMACOLOGY Mechanism of Action: Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Patients with asthma were found in one study to be 25­ 100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and Reference ID: 3407275 inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Inhalational challenge studies in sensitized sheep showed that zafirlukast suppressed the airway responses to antigen; this included both the early- and late-phase response and the nonspecific hyperresponsiveness.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson Et Al
    US006319953B1 (12) United States Patent (10) Patent No.: US 6,319,953 B1 Carlson et al. (45) Date of Patent: *Nov. 20, 2001 (54) TREATMENT OF DEPRESSION AND WO 95/08549 3/1995 (W0). ANXIETY WITH FLUOXETINE AND AN WO 95/18124 7/1995 (W0). NK-1 RECEPTOR ANTAGONIST W0 96/05181 2/1996 (W0). W0 96/18643 6/1996 (W0). (75) Inventors: Emma Joanne Carlson, Puckeridge; W0 96/19233 6/1996 (W0). Nadia Melanie Rupniak, Bishops W0 96/24353 8/1996 (W0). W0 98/15277 4/1998 (W0). Stortford, both of (GB) OTHER PUBLICATIONS (73) Assignee: Merck Sharp & Dohme Ltd., Hoddesdon (GB) Aguiar, M., et al., Physiology& Behavior, 1996, 60(4) 1183—1186. ( * ) Notice: Subject to any disclaimer, the term of this Barden, N., et al., J. Neurochem., 1983, 41, 834—840. patent is extended or adjusted under 35 BristoW, L., et al., Eur J. Pharmacol., 1994, 253, 245—252. U.S.C. 154(b) by 0 days. Brodin, E., et al., Neuropharmacology, 1987, 26(6) 581—590. This patent is subject to a terminal dis Brodin, E., et al., Neuropeptides, 1994, 26, 253—260. claimer. Culman, J., et al., J. Physiol. Pharmacol., 1995, 73, 885—891. Cutler, et al., J. Psychopharmacol, 1994, 8, A22, 87. (21) Appl. N0.: 09/457,241 Elliott, P. J., Exp. Brain Res. UK, 1988, 73, 354—356. (22) Filed: Dec. 8, 1999 F—D—C Reports—Prescription Pharmaceuticals and Bio technology, Dec. 8, 1997, 59(49), 10. Related US. Application Data File, S. E., Pharm. Biochem. Behavior, 1997, 58, 3, 747—752. (60) Division of application No.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Farmacopea De 2021 (Lista De Medicamentos Cubiertos)
    Planes Medicare Advantage de ConnectiCare Plan ConnectiCare Choice 1 (HMO) Plan ConnectiCare Choice 2 (HMO) Plan ConnectiCare Choice 3 (HMO) Plan ConnectiCare Choice Part B Saver Plan ConnectiCare Flex 1 (HMO-POS) Plan ConnectiCare Flex 2 (HMO-POS) Plan ConnectiCare Flex 3 (HMO-POS) Plan ConnectiCare Passage 1 (HMO) Farmacopea de 2021 (Lista de medicamentos cubiertos) LEA LA SIGUIENTE INFORMACIÓN: ESTE DOCUMENTO CONTIENE INFORMACIÓN SOBRE LOS ME- DICAMENTOS QUE CUBRIMOS EN ESTE PLAN. 00021082, V17 Esta farmacopea se actualizó el 09/01/2021. Para obtener información más reciente o si tiene otras preguntas, comuníquese con Servicios para Miembros de ConnectiCare al 1-800-224-2273, los usuarios de TTY deben llamar al 711, de 8.00 am a 8.00 pm, hora del este, los siete días de la semana, o visite connecticare.com/medicare. Última actualización 09/01/2021 H3528_200567_C Nota para los miembros existentes: Esta farmacopea se ha cambiado desde el año pasado. Revise este documento para asegurarse de que aún se incluyan los medicamentos que usted toma. Cuando esta lista de medicamentos (farmacopea) haga referencia a “nosotros”, “nos” o “nuestro”, significa ConnectiCare. Cuando se refiere a “plan” o “nuestro plan”, significa los planes Medicare Advantage de ConnectiCare. Nuestros planes Medicare Advantage incluyen los planes ConnectiCare Choice 1 (HMO), ConnectiCare Choice 2 (HMO), ConnectiCare Choice 3 (HMO), ConnectiCare Choice Part B Saver, ConnectiCare Flex 1 (HMO-POS), ConnectiCare Flex2 (HMO-POS), ConnectiCare Flex 3 (HMO-POS) y ConnectiCare Passage 1 (HMO). Este documento incluye una lista de los medicamentos (farmacopea) para nuestro plan que se encuentra vigente desde el 09/01/2021 .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Medicare Part D: 2021 Value Plan Formulary
    | Value Plan | Express Scripts Medicare (PDP) 2021 Formulary (List of Covered Drugs) PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN Formulary ID Number: 21095, Version 10 This formulary was updated on 9/1/2021. For more recent information or other questions, please contact Express Scripts Medicare® (PDP) Customer Service at 1.800.758.4574; New York State residents: 1.800.758.4570 or, for TTY users, 1.800.716.3231, 24 hours a day, 7 days a week, or visit express-scripts.com. Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take. When this drug list (formulary) refers to “we,” “us,” or “our,” it means Medco Containment Life Insurance Company and Medco Containment Insurance Company of New York (for members located in New York State only). When it refers to “plan” or “our plan,” it means Express Scripts Medicare. This document includes a list of the drugs (formulary) for our plan, which is current as of September 1, 2021. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages. You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year. What is the Express Scripts Medicare Formulary? A formulary is a list of covered drugs selected by Express Scripts Medicare in consultation with a team of healthcare providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program.
    [Show full text]